Ocular myasthenia

1 trials MedDRA PT
1 Registered trials
0 Recruiting
1 Unique sponsors
1 Unique IMPs
1 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
FcRn antagonist 1 substance
Phase III: 1

Filter these 1 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 1 trials

Phase III

1 trial
  • Argenx Commercial
    EFGARTIGIMOD ALFA
    2024-514133-38-00 15 countries 2025 n=169 Orphan
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Argenx Commercial 1 Phase III 0
New trials by year
2025
1
← All indication landscapes